Posted by AGORACOM-JC
at 4:23 PM on Monday, November 9th, 2020
Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in 280 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” … and if that is all they had you would have the makings of a great small cap cannabis company.
But there is more …. way more.
Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona. More than just lip service:
Venom just surpassed $30,000,000 (MILLION) in revenue YEAR TO DATE
Venom Extracts is one of Arizona’s premier extract brands
One of the state’s largest producers of medical cannabis distillate and related products
The products are award winning
….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen
THE NUMBERS SAY IT ALL
1. RECORD Q3 REVENUE $12.5M
2. CRAZY REVENUE GROWTH 5,200%
3. RECORD EBITDA $1.265M (vs a loss of $362,000) In case you’re wondering if this was a fluke quarter, this is what Q2 looked like:
RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year
HOLLISTER HEADED TOWARDS $50,000,000 REVENUE?
If you’re paying attention, HOLL is achieving enormous growth both year over year and sequentially. If we extrapolate the latest Q3 numbers, Hollister is on a $50,000,000 annualized revenue run rate assuming no further growth.
But there is more.
The State of Arizona just approved recreational cannabis in Arizona. This is a potential windfall for Venom given the fact its brand, reputation and dispensary penetration from its award winning medical cannabis is about as good as it gets. How good is Hollister now?
How good does it get?
Watch this incredible interview with Venom Extracts Founder Jake Cohen, the coolest exec in small cap cannabis because he delivers incredible results with sweat, swagger and great swag to boot.
Posted by AGORACOM-JC
at 3:59 PM on Monday, November 9th, 2020
Closed its previously announced private placement of units of the Company, which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit for aggregate gross proceeds of $1,228,356.55
The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner
VANCOUVER, BC / November 9, 2020 / Empower Clinics Inc. (“Empower” or the “Company“) (CSE:CBDT), is pleased to announce that it has closed its previously announced private placement of units of the Company (the “Units“), which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit (the “Offering Price“) for aggregate gross proceeds of $1,228,356.55 (the “Offering“). The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“).
Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“), with each Warrant exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.
The Company is also pleased to announce that Steven McAuley, the Chief Executive Officer a director of the Company, participated in the Offering by subscribing for 1,200,000 Units for $60,000.
The Company intends to use the net proceeds raised under the Offering to support the objective of clinic growth, lab testing services, sales and marketing, for general working capital purposes.
In connection with the Offering, the Agent received an aggregate cash fee of $88,000. In addition, the Company granted the Agent compensation options (the “Compensation Options“) exercisable for 1,760,000 Units at an exercise price equal to the Offering Price for a period of 24 months following the closing of the Offering.
The subscription by Mr. McAuley is deemed, “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation requirements of MI 61-101 since none of the securities of the Company are listed on a stock exchange specified in section 5.5(b) thereof. The transaction is exempt from the minority shareholder approval requirements of MI 61-101 since, at the time the transaction was agreed to, neither the fair market value of the transaction nor the fair market value of the consideration for the transaction, insofar as it involves interested parties, exceeded 25% of the Company’s market capitalization.
The securities issued pursuant to the Offering will be subject to a four-month hold period under applicable securities laws in Canada.
In connection with the Offering, $18,356.55 of the subscription funds are a result of a settlement with an arm’s length service provider of through the issuance of 367,131 Units.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with an expanded suite of physician-based services. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability and will lead our diagnostic and scientific advancement.
Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Posted by AGORACOM
at 8:28 AM on Friday, November 6th, 2020
OAKLAND, Calif. and TORONTO, Nov. 6, 2020 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced today that it is engaging in a substantial upgrade of one of its approximately 45,000 square foot greenhouses at its 47-acre integrated production campus in Salinas, California (the “Salinas Facility”).
The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights in the greenhouse. Following the successful completion of these upgrades, on an annualized basis. the Company expects an approximately 50% increase in production from this greenhouse, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity of the Salinas Facility. The project is expected to be completed within the first quarter of 2021 and the Company expects that the total cost of the updates will be fully recouped within the first twelve months of operation following completion of the project.
In addition, the Company announced today that its in-house brand, Harborside Farms, a highly recognized, customer-centric product line, will commence sales of clones grown at its Salinas Facility at all Harborside branded locations, including Desert Hot Springs. On a year-over-year basis, sales of Harborside Farms products have grown by 229% at Harborside’s iconic dispensaries capturing 42% of its total retail flower sales through the end of the third quarter of 2020, demonstrating continuing strength and customer loyalty to one of its flagship brands.
“We have carved out a strong reputation for supplying high-quality cannabis products to the growing California market and these upgrades are a crucial investment that will fuel our growth heading into 2021,” said Peter Bilodeau, Interim CEO and Chairman of Harborside. “Leveraging the strength of our Salinas facility, we’re thrilled to be officially commencing sales of clones that are grown at our farm and only available at our stores immediately. This new in-house product category was developed utilizing sustainable cultivation techniques to provide discerning consumers with access to locally grown, high-quality cannabis.”
The Company’s clone initiative aims to capitalize on these trends and the continued high-quality production from its Salinas Facility, and will underscore the single-source, local nature of the Harborside Farms brand, as well as its emphasis on sustainable cultivation practices. The initiative will also continue to enhance the Company’s retail gross margins by adding an additional in-house product category sourced internally from its Salinas Facility.
At its retail dispensaries, clones (inclusive of seeds and seedlings) are expected to comprise approximately 5% of the Company’s total annual retail sales, or approximately $2M in annual net retail revenue in 2020. The Company’s average gross margin in this category is approximately 52% through the end of the third quarter. The Company anticipates Harborside Farms clones capturing at least 50% of total clone sales throughout the course of 2021, resulting in total sales of approximately $1M, with estimated gross margins as high as 90%. The Company expects average gross margins across its entire clones category to increase to approximately 70% during 2021 as a result of this initiative, providing an approximate 18% improvement over its expected annual average gross margin in this category as compared to 2020.
About Harborside: Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.
Posted by AGORACOM-JC
at 1:54 PM on Thursday, November 5th, 2020
Kontrol BioCloud® a Safe Space Technology™ –
Announced that it has received CSA standards approval for its BioCloud® technology
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol
CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety
TORONTO, ON / ACCESSWIRE / November 5, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received CSA standards approval for its BioCloud® technology.
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”
Field Certification was provided by ESAFE
CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety. The field evaluation process follows the CSA’s SPE-1000 standard, which has three mandatory and non-destructive tests. Upon successful inspection, ESAFE validates the equipment meets CSA’s SPE-1000 standards and labels it approved. ESAFE’s labels are recognized across Canada under the Standards Council of Canada accreditation program.
ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.
BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others
BioCloud®is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com.
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud® Analyzer are subject to the risk that the Kontrol BioCloud® Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 10:58 PM on Wednesday, November 4th, 2020
Company comments on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona
“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024…” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .
VANCOUVER, BC , Nov. 4, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona provides comment on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona .
“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .
Arizona Presence
Hollister , through its 100% owned subsidiary, Venom Extracts (” Venom “), is one of Arizona’spremier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products. With an experienced management team and unparalleled reputation for quality, Venom prides itself as a differentiated extraction company by producing legal cannabis products at a price point that allows retailers to generate higher profits. Focused on proprietary efficiencies, Venom is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CAbirthplace of the “American Biker”.
The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Posted by AGORACOM-JC
at 5:51 PM on Wednesday, November 4th, 2020
InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research
Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).
There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).
Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.
Why CBD and Why Now?
CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.
CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.
The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.
Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.
Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3
Posted by AGORACOM-JC
at 2:15 PM on Wednesday, November 4th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 280 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA. Learn More.
“Until now, Arizona had imposed some of the strictest prohibition laws in the country; in some instances, the possession of even small amounts of marijuana was classified as a felony,” NORML Executive Director Erik Altieri said. “By rejecting this failed policy, no Arizonan going forward will be saddled with a criminal conviction for engaging in the personal possession or cultivation of cannabis, or face the lifelong stigma that comes with it.”
“Proposition 207 will disrupt the illicit market, end low-level marijuana arrests, create jobs and new revenue,” he added. “This result once again shows that marijuana legalization is not exclusively a ‘blue’ state issue, but an issue that is supported by a majority of all Americans—regardless of party politics.”
Polling was mixed heading into Election Day, with surveys consistently showing the proposal ahead, though by differing margins. In September, the Smart and Safe Arizona campaign shared an internal poll with Marijuana Moment that showed 57 percent of likely voters supported the initiative, but a separate survey found just 46 percent in favor of the policy change. Additional polls last month showed the cannabis measure with a significant and growing lead.
The measure also contains several restorative justice provisions such as allowing individuals with prior marijuana convictions to petition the courts for expungements and establishing a social equity ownership program.
Cannabis sales will be taxed at 16 percent. Tax revenue will cover implementation costs and then be divided among funds for community colleges, infrastructure, a justice reinvestment and public services such as police and firefighters.
The Department of Health Services will be responsible for regulating the program and issuing cannabis business licenses. It will also be tasked with deciding on whether to expand the program to allow for delivery services.
The law technically goes into effect upon passage and after the voters are certified, which is expected to take place on November 30. After that point adults could legally use, possess and cultivate cannabis. However, regulators will still have to promulgate rules for overseeing the commercial industry. They can issue licenses starting in January 2021, and the first shops could be approved by February 1.
“Just four years after legalization was narrowly defeated, voters in Arizona turned out to send a clear message that they support marijuana legalization,” Steve Hawkins, executive director of the Marijuana Policy Project, said. “Following this victory, adults will no longer be treated as criminals for using a substance that is safer than alcohol and will be able to access it from safe and regulated businesses.”
Like other drug policy reform campaigns throughout the U.S., Smart and Safe Arizona faced significant obstacles qualifying its measure for the ballot amid the coronavirus pandemic.
At one point, activists asked the state Supreme Court to allow them to collect signatures electronically amid social distancing mandates, but that request was rejected.
Ultimately, the campaign submitted about 420,000 raw signatures. Secretary of State Katie Hobbs said that her office verified the petitions and determined that approximately 255,080 valid signatures were turned in. At least 237,645 were needed to qualify.
Opponents of the proposal, including Gov. Doug Ducey (R), released official voter guide arguments against the initiative in August. Supporters filed arguments as well, and all were circulated to voters in a pamphlet printed by the state.
Prohibitionists also released a series of attack ads that including misleading claims about what the measure would do and what has occurred in states that have already enacted cannabis legalization.
Posted by AGORACOM-JC
at 7:26 AM on Monday, November 2nd, 2020
Announced that it will be participating at this year’s NASPGHAN (North American Society for Pediatric Gastroenterology, Hepatology and Nutrition), November 1 st to 7 th
Else’s virtual booth will enable live conversations with small groups, and one-on-one educational sessions, among the nearly 2,600 anticipated attendees
The forum will place Else Nutrition alongside some of the leading blue-chip nutrition companies, including Pfizer, Abbott Laboratories, Nestle and Danone
VANCOUVER, BC , Nov. 2, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (” Else ” or the ” Company “), a developer of plant-based alternatives to dairy-based baby nutrition, is pleased to announce that it will be participating at this year’s NASPGHAN (North American Society for Pediatric Gastroenterology, Hepatology and Nutrition), November 1 st to 7 th . Else’s virtual booth will enable live conversations with small groups, and one-on-one educational sessions, among the nearly 2,600 anticipated attendees. The forum will place Else Nutrition alongside some of the leading blue-chip nutrition companies, including Pfizer, Abbott Laboratories, Nestle and Danone.
“We are working diligently to build awareness of our products with America’s top pediatricians and medical experts” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else. “We want them to form their own unbiased opinion of ELSE’s health benefits for babies and we are excited to introduce and promote our plant-based product to this professional crowd at NASPGHAN . Educating the medical community is a major pillar of our marketing strategy,” she added.
This year’s annual summit is virtual due to COVID-19.
Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com , and on Amazon.com.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean, plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition organizations. Many of Else advisory board members held executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in prominent roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 7:23 AM on Monday, November 2nd, 2020
2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:
2019 + 86% To $2.03M
Q4 + 217% To $625,000
Q1 + 416% To $790,000
Q2 + 56% To $923,000
This performance has translated into the following year-to-date in 2020:
Revenue $1.7M vs $745K = 130% Growth
Patient Visits 12,400 vs 5,500 = 125% Growth
VANCOUVER BC / November 2, 2020 / EMPOWER CLINICS INC. Empower Clinics (CBDT:CSE)(EPWCF:OTC)(8EC:FRA) (the “Company” or “Empower“), an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to provide shareholders with a status report on many initiatives announced over the past several weeks for the purposes of providing greater visibility into the Company’s outlook into 2021.
Steven McAuley, CEO of Empower Clinics stated “2020 is the year that established Empower Clinics as a formidable Health & Wellness Company with a solid foundation and great growth prospects. Given the speed at which we have been moving since I took over the leadership reigns in 2019, it is prudent to take a moment to provide our shareholders with both a current snapshot, as well as, our expectations for continued growth into 2021.”
HIGHLIGHTS & UPDATES
2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:
2019 + 86% To $2.03M
Q4 + 217% To $625,000
Q1 + 416% To $790,000
Q2 + 56% To $923,000
This performance has translated into the following year-to-date in 2020:
Revenue $1.7M vs $745K = 130% Growth
Patient Visits 12,400 vs 5,500 = 125% Growth
Going forward, given the Company’s diversification into telemedicine, COVID-19 testing, medical laboratory testing for enterprise customers, and the proposed clinic expansion into Canada, all of which serves to diversify Empower well beyond our Southwestern U.S. clinic operations, going forward “patient visits” will be just one of many of the Company’s overall KPI’s (Key Performance Indicators).
Kai Medical Laboratory COVID-19 Testing Growth Includes Film & Television Industry Empower completed the closing of the Kai Medical Laboratory acquisition with the signing of the Member Purchase Interest Agreement October 5, 2020 and then subsequently completed the filing of all required regulatory documents with the State of Texas and other regulatory bodies.
The Company is now working through integration and implementing aggressive growth strategies including servicing new COVID-19 testing contracts for the film & television industry and supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.
Sun Valley Health COVID-19 Regional Testing Growth Sun Valley Health with the support of Kai Medical Laboratory testing and medical billing capabilities, is expanding its RT-PCR testing with the commencement of drive-up testing for consumers in Mesa, Arizona and within clinic locations. The program allows the Company to provide free COVID-19 testing for consumers with Medicare and Medicaid insurance coverage in Arizona and for consumers who do not have active health insurance coverage in the state.
$1,100,000 Proposed Private Placement The previously announced proposed private placement with Mackie Research Capital Corporation as sole agent and sole bookrunner (the “Agent”) on October 21, 2020 remains on track for closing as planned on or about the week of November 2, 2020.
Canadian Clinic Acquisition The recently announced non-binding term sheet for the acquisition of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health”) is progressing as planned through the final due diligence phase with an anticipated closing in November 2020.
Q3 2020 Financial Statements The Company anticipates filing its third quarter 2020 financial statements and MD&A well in advance of the November 30, 2020 filing deadline. Financial and accounting controls supported by CFO Kyle Appleby enable the Company to maintain high compliance standards.
McAuley went on to say “Our company is rapidly evolving into providing an integrated healthcare experience that spans from testing to treatment by combining cutting edge technologies including telemedicine and state of the art lab testing. Add to this the fact that we are now serving enterprise level clients as promised and partnering on initiatives such as our recently announced travel bubble, it’s safe to say we are on the path to becoming a formidable small cap health & wellness company in 2021. I want to thank our loyal shareholders for trusting my leadership transition, welcome all of our newest shareholders and we look forward to delivering continued accelerated growth in 2021 and well beyond.”
ABOUT EMPOWER:
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with an expanded suite of physician-based services. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability and will lead our diagnostic and scientific advancement.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the anticipated date of closing of the Momentum Health acquisition and the occurrence thereof; the expected number of clinics and patients following the proposed closing; the future potential success of Kai Medical Laboratory; the future success of the Sun Valley’s franchise model; the completion of the private placement, date of closing or the occurrence of a closing; the impact if any of COVID-19 testing by Sun Valley Health and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
View original content to download multimedia: 
